94790-24-6

Basic information

• Product Name: oc-O-Methyl-L-TyrosineMethylEster
• Synonyms: oc-O-Methyl-L-TyrosineMethylEster;METHYL (2R)-2-[(TERT-BUTOXY)CARBONYLAMINO]-3-(4-METHOXYPHENYL)PROPANOATE;Methyl N-Boc-O-methyl-L-tyrosinate;(S)-2-[(tert-Butoxycarbonyl)amino]-3-(4-methoxyphenyl)propionic acid methyl ester;N-tert-Butoxycarbonyl-O-methyl-L-tyrosine methyl ester;O-methyl-N-tert-butoxycarbonyl-L-tyrosine methyl ester;Boc-4-methoxy-L-phenylalanine methyl ester;Boc-L-Tyr(Me)-OMe
• CAS NO: 94790-24-6
• Molecular Formula: C₁₆H₂₃NO₅
• Molecular Weight: 309.36
• Mol File: 94790-24-6.mol
• Article Data: 47

Chemical Properties

• Appearance: /
• CAS DataBase Reference: oc-O-Methyl-L-TyrosineMethylEster(CAS DataBase Reference)
• NIST Chemistry Reference: oc-O-Methyl-L-TyrosineMethylEster(94790-24-6)
• EPA Substance Registry System: oc-O-Methyl-L-TyrosineMethylEster(94790-24-6)

Safety Data

• Hazardous Substances Data: 94790-24-6(Hazardous Substances Data)

Usage

Description

oc-O-Methyl-L-TyrosineMethylEster is a chemical compound derived from the amino acid tyrosine, specifically as an ester derivative of 3-O-methyl-L-tyrosine. It is primarily utilized in the fields of organic chemistry and biochemistry for research purposes. oc-O-Methyl-L-TyrosineMethylEster has demonstrated potential pharmacological properties, making it a promising candidate for drug development. Furthermore, it has been investigated for its possible therapeutic role in the treatment of specific neurological and psychiatric disorders. However, additional research is necessary to fully comprehend its biological activities and potential applications in medicine.

Uses

Used in Organic Chemistry Research:
oc-O-Methyl-L-TyrosineMethylEster is used as a research compound in organic chemistry for studying its chemical properties and potential reactions with other molecules.
Used in Biochemical Research:
In biochemistry, oc-O-Methyl-L-TyrosineMethylEster serves as a research tool to explore its interactions with biological systems and understand its role in various biochemical processes.
Used in Drug Development:
oc-O-Methyl-L-TyrosineMethylEster is used as a potential candidate in drug development due to its demonstrated pharmacological properties, which may lead to the creation of new therapeutic agents.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, oc-O-Methyl-L-TyrosineMethylEster is utilized for the development and testing of new drugs, particularly those targeting neurological and psychiatric disorders.
Used in Treatment of Neurological and Psychiatric Disorders:
oc-O-Methyl-L-TyrosineMethylEster is studied for its potential role in the treatment of certain neurological and psychiatric disorders, with the aim of providing new therapeutic options for patients.

Upstream product

• 3978-80-1 Boc-Tyr-OH 
• 74-88-4 methyl iodide 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 93267-04-0 N-(tert-butoxycarbonyl)-L-3-iodoalanine methyl ester 
• 4326-36-7 (S)-N-(tert-butoxycarbonyl)tyrosine methyl ester 
• 67-56-1 methanol 
• 3978-80-1 N-t-butyloxycarbonyl-L-tyrosine 
• 69942-12-7 N-tert-butoxycarbonylserine methyl ester 
• 175844-11-8 methyl (2R)-2-[(tert-butoxycarbonyl)amino]-3-bromopropionate 
• 1080-06-4 L-Tyr-OMe 
• 35448-10-3 oxalic acid mono-tert-butyl ester 
• 17355-19-0 methyl (S)-2-amino-3-(4-methoxyphenyl)propionate 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 60-18-4 L-tyrosine 

Downstream Products

• 68856-96-2 N-(tert-butoxycarbonyl)-O-methyl-D-tyrosine 
• 120349-75-9 (2R)-2-(tert-butoxycarbonyl)amino-3-(4-methoxyphenyl)propan-1-ol 
• 400009-27-0 (R)-2-Dibenzylamino-3-(4-methoxy-phenyl)-propionaldehyde 
• 400009-28-1 (R)-2-Dibenzylamino-3-(4-methoxy-phenyl)-propan-1-ol 
• 400009-34-9 (R)-2-Dibenzylamino-3-(4-methoxy-phenyl)-propionic acid methyl ester 
• 400009-30-5 (2S,3S,4R)-benzyloxy-4-N,N-dibenzylamino-3-hydroxy-5-(4'-methoxy-phenyl)pentan-1-ol 
• 70601-64-8 (R)-4-methoxyphenylalanine methyl ester hydrochloride 
• 1610691-82-1 (R)-N-(2-chloroacetyl)-4-methoxyphenylalanine methyl ester 
• 1610691-86-5 (R)-N-[N-(2,2-dimethoxyethyl)glycinyl]-4-methoxyphenylalanine methyl ester 
• 53267-93-9 O-methyl-N-tert-butoxycarbonyl-L-tyrosine 
• 121778-79-8 methyl (4S,5R)-5-(4-methoxyphenyl)-2-oxo-1,3-oxazolidine-4-carboxylate 
• 126395-29-7 [(S)-2-hydroxy-1-(4-methoxybenzyl)ethyl]carbamic acid tert-butyl ester 
• 17355-19-0 methyl (S)-2-amino-3-(4-methoxyphenyl)propionate 
• 111687-94-6 (S)-2-(p-methoxyphenyl)methyl-2,5-dihydropyrrole 

Relevant articles and documents

Preparation method of chiral alpha-methyl arylethylamine

The invention provides a preparation method of chiral alpha-methyl arylethylamine, and relates to the technical field of organic synthesis medicines. Boc-amino acid methyl ester is used as an initial raw material, Boc-amino alcohol is obtained through reduction, Boc-amino alcohol reacts with thionyl chloride and is oxidized through sodium periodate to obtain a sulfonamide compound, and then the sulfonamide compound is reduced through sodium borohydride promoted by lewis acid and a protecting group is removed under the acidic condition to obtain a target compound. According to the method, raw materials are cheap and easy to obtain, a single optical isomer product is obtained by using chiral raw materials, the problem of column chromatography resolution is solved, generation of a large amount of solid wastes and isomers is avoided, atom economy is improved, the product purity is high, the yield is high, and the production cost is effectively reduced. In addition, the mild reduction system is used for replacing the original high-pressure hydrogenation reaction, the process operation is relatively simple, and the method is more suitable for large-scale industrial production.

BORYLATED AMINO ACID COMPOSITIONS FOR USE IN BORON NEUTRON CAPTURE THERAPY AND METHODS THEREOF

Borylated Amino Acid ("BAA") compositions and methods of making BAAs are disclosed herein. Consequently, the BAAs can be administered to patients as a Neutron Capture Agent and provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome

A series of tripeptidic proteasome inhibitors with furylketone as C-terminus were designed and synthesized. Biochemical evaluations against β1, β2 and β5 subunits revealed that they acted selectively on β5 subunit with IC50s against chymotrypsin-like (CT-L) activity in micromolar range. LC-MS/MS analysis of the ligand-20S proteasome mixture showed that the most potent compound 11m (IC50 = 0.18 μM) made no covalent modification on 20S proteasome. However, it was identified acting in a slowly reversible manner in wash-out assay and the reversibility was much lower than that of MG132, suggesting the possibility of these tripeptidic furylketones forming reversible covalent bonds with 20S proteasome. Several compounds were selected for anti-proliferative assay towards multiple cancer cell lines, and compound 11m displayed comparable potency to positive control (MG132) in all cell lines tested. Furthermore, the pharmacokinetic (PK) data in rats indicated 11m behaved similarly (Cmax, 2007 μg/L; AUC0?t, 680 μg/L·h; Vss, 0.66 L/kg) to the clinical used agent carfilzomib. All these data suggest 11m is a good lead compound to be developed to novel anti-tumor agent.